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Rupture of the coronary artery fibrous cap is a common cause of myocardial infarction, and bone marrow derived cells could
play a role in preventing plaque rupture. It is currently unknown whether smooth muscle cells within coronary artery fibrous cap
formation are of mature phenotype. Objective. To characterize cells expressing bone marrow stem cells of embryonic type (ESC)
markers in coronary artery fibrous cap formation. Design. New Zealand White rabbits were fed a diet supplemented with 0.5%
cholesterol + 1% methionine + 5% peanut oil for 4 weeks and then a normal diet for 9 weeks. The left main coronary artery was
excised from the heart, processed for paraffin and immunohistochemistry was performed by standard techniques. Results. Oct-4,
SSEA 1, 3, and 4 were all present within in atherosclerotic plaque core, codistributed with RAM-11, and were sparingly found in the
fibrous cap, but TRA-1-60 and TRA-1-81 positive cells were scarce. Core but not fibrous cap smooth muscle (SMC𝛼 actin+) cells
also showed codistribution with ESC markers. Conclusions. These results suggest that smooth muscle cells present in the fibrous
cap do not express ESC markers, indicative of a mature cell.
1. Introduction
Rupture of coronary artery fibrous cap is a major cause of
myocardial infarct [1]. Inhibition of the HMGCoA reductase
enzyme and renin angiotensin system have been one of the
most successful therapies in reducing this burden, possibly by
increasing the formation of a stable fibrous cap. Interestingly,
stem cells can be regulated by the same pharmacological
therapy, providing a possible explanation as to the beneficial
effects of treatments [2]. For example, simvastatin has been
shown to normalise endothelial progenitor cells in obese
patients to those observed in nonobese controls [3] and
angiotensin II receptor blockers increased endothelial pro-
genitor cells in diabetic patients [4], and modulation of these
types of cells is also observed with angiotensin converting
enzyme inhibitors [5]. Thus, the characterization of stem cell
populations in coronary artery diseasewill aid in understand-
ing whether standard pharmacological treatments can affect
the population of such undifferentiated cells. Recent studies
have suggested that the origin of smooth muscle cells in
atherosclerotic fibrous capsmight not be from the circulation
[6] as had been enthusiastically embraced but derive from
the local medial SMC layer [7, 8]. Thus, in this study, it was
hypothesised that if smooth muscle cells originated from the
circulation and were of primitive type, then the cells in the
fibrous cap should express markers of primitive cell origin.
Adult bone marrow harbours several population of stem
cells, such as endothelial progenitor cells, mesenchymal
stromal cells, and very small embryonic-like cells which all
express markers of pluripotency [9, 10]. For example, human
very small embryonic-like cells express a range of markers,
including Oct-4, SSEA-4 [9, 10], endothelial progenitor cells
express CD34, CD133, and the VEGF receptor [11], and
mesenchymal stromal cells extracted from human placenta
express SSEA-1, SSEA-3, SSEA-4, Tra-1-60, Tra1-81, and Oct-
4 [12].We have reported the positive identification ofmarkers
of primitive cell origin and endothelial precursor cells in
human and rabbit atherosclerosis. CD34+ cells [13] and
embryonic stem cell markers, octomer-4 (Oct-4), the SSEA
1, 3, and 4, TRA-1-60, and TRA-1-81 [14] have been identified
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in rabbit atherosclerotic vessels and human diseased arteries
[15]. Oct-4 is a transcription factor, and its downregulation is
believed to trigger the differentiation of the undifferentiated
cell [16]. Stage-specific embryonic antigens (SSEAs) are asso-
ciated with cell adhesion, migration, and differentiation and
are often differentially expressed during development [17],
whereas tumor rejector antigens (TRAs) were first developed
for antibody-based treatments for cancer [18].
As the identification and localisation of cells expressing
markers of pluripotency within coronary artery atheroma-
tous plaques have not yet been performed, we sought to use
immunohistochemistry to identify the specific location of
such cells within the fibrous cap and core of the atheroscle-
rotic lesion and to regionally compare this with macrophages
and smooth muscle cells.
2. Methods
Male New Zealand White rabbits at three months of age
were fed a normal rabbit chow diet supplemented with 0.5%
cholesterol plus 1% methionine plus 5% peanut oil for 4
weeks and then a normal chow diet for 9 weeks to induce
fibrous cap formation [19]. The animals were housed in
individual cages and maintained at a constant temperature of
approximately 21∘C. Food andwaterwere supplied ad libitum.
The experiments were carried out according to the National
Health and Medical Research Council “Australian Code of
Practice for the Care and Use of Animals for Scientific
Purposes” (6th Edition, 1997). The animals were sacrificed
by an overdose of ketamine and xylazine, the hearts were
removed, and the left main coronary artery was excised,
fixed in 4% paraformaldehyde solution in 1xPBS overnight,
processed for paraffin, and mounted on one paraffin block
[19]. The block was mounted on a microtome (Microm,
HM325, ThermoScientific Australia) and 5𝜇m ribbons were
collected and placed onto a 48∘C hot water bath [14]. Once
sections expanded to normal block size, serial sections were
collected onto microscope slides, labelled, and dried in a
37∘C oven overnight. Slides were then stored in an airtight
container.
2.1. Immunohistochemistry. As double labelling techniques
cannot be used in rabbit models, as a mouse and rabbit
primary antibody is necessary, we used serial sections to
identify cells. The use of an anti-rabbit secondary antibody
will lead to high nonspecific binding of IgG present in cells.
Oct-4, SSEA1, SSEA3, SSEA4, TRA-1-60, and TRA-1-
81 monoclonal antibodies were purchased from Millipore
USA [14]. RAM-11 was purchased from DAKO cytomation
and HHF-35 (rabbit SMC𝛼 actin) from Millipore, USA.
All primary antibodies were diluted 1 : 100 and incubated
overnight. For the negative control, amonoclonal antibody to
Aspergillus niger glucose oxidase (DAKO Corporation, USA)
was diluted 1 : 20 and incubated overnight. Then, immuno-
histochemistry was performed as previously described in our
laboratory [19, 20]. The block was mounted on a microtome
(Microm, HM325, ThermoScientific Australia) and 5 𝜇m
ribbons were collected and placed onto a 48∘C hot water
bath [14]. Once sections expanded to normal block size, serial
sections were collected onto microscope slides, labelled, and
dried in a 37∘C oven overnight. Slides were then stored in an
airtight container.
3. Results
In the left main coronary artery, RAM-11 positive macro-
phages were observed throughout the plaque (Figure 1(a))
and also sporadically within the fibrous cap (magnified
images beneath Figure 1(a)). Oct-4 showed a similar pattern
and codistributed with RAM-11 as observed (Figure 1(b) and
magnified images beneath (b), dashed circles). SMC𝛼 actin
positive cells (HHF35) were identified as spindle shaped
cells in the fibrous cap, as well as macrophage-like cells that
coexpressed Oct-4 within cells of the fibrous cap (arrows,
Figure 1(c) and images beneath (c)). Coexpression of SMC𝛼
actin, RAM-11, Oct-4, and SSEA-4 (Figures 1(d) and 2(a)) was
observed in the core (Figures 1(a), 1(b), 1(c), and 1(d)).
Interestingly, the spindle shaped SMC𝛼 actin positive
cells within the cap (Figure 1(c) bottom image) did not show
reactivity to Oct-4 or other ESC markers tested (Figures
2(a)–2(g)), although nonspindle shaped SMC𝛼 actin positive
cells within the core were immunoreactive with SSEA1, 3,
4. In addition, the endothelial layer overlying the fibrous
cap did show positive immunoreactivity Oct-4, SSEA-1, 3,
and 4. This staining was present in specific “endothelial like”
cells overlying the cap (Figures 2(c) and 2(d)) as well as the
endothelial layer (Figures 2(b)–2(f)).
Tra-1-60 (Figure 2(c)) and Tra-1-81 (Figure 2(g)) showed
no positive endothelial staining cells and no positive core
staining cells; however, specific single cells were present
either overlying plaques (Figure 2(c) insert) or just beneath
the endothelium (Figure 2(g)), and these cells codistributed
with RAM-11 (Figure 1(a) bottom image), indicative of
macrophages.
Negative control showed no immunoreactivity (Fig-
ure 2(h)).
4. Discussion
The major finding in this investigation is that the fibrous
cap formed in the left main coronary artery of rabbits
contain spindle shaped SMC𝛼 actin positive cells that do not
codistribute with ESC markers. However, the core contains
abundant cells positive for ESC markers and SMC𝛼 actin
positive cells. Furthermore, Tra-1-81 and 1-60 are scarcely
present in plaques.
The beneficial role of stem cells in atherogenesis remains
unclear. Although clinical studies show a possible beneficial
role for stem cell therapy in cardiac repair [21], the opposite
appears to hold true in animal model studies of atheroscle-
rotic disease. For example, Silvestre and colleagues show
that the injection of bone marrow-derived mononuclear cells
increased aortic sinus atherosclerotic lesions up to 72% [22].
The authors argue that as plaque collagen and smoothmuscle
cells also increase, plaque stability was uncompromised. On
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Figure 1: Photomicrographs of serial adjacent sections of the leftmain coronary artery. Photos are arranged in columns. Macrophage (RAM-
11) positive cells are abundant throughout the plaque ((a), ×40, scale bar 250𝜇m), and also sporadically within the fibrous cap ((a), exploded
view,×400, scale bar 18 𝜇m).These results were very similar toOct-4 staining (b), indicative thatmacrophagesmight be primitive cells (arrows
and dashed circles). In addition, SMC𝛼 actin positive cells were visible throughout the plaque (c), specifically represented as spindle shaped
cells in the formed cap ((c), exploded view, scale bar 8𝜇m), as well as overlying the endothelial layer. SSEA-4 positive immunolabled cells
were also present in the endothelial layer and coronary artery core, and this was similar to RAM-11, Oct-4, and SMC𝛼 actin positive cells. No
spindle shaped cells were present in the coronary artery fibrous cap that also reacted with any ESC marker.
the other hand, George and colleagues show that endothe-
lial progenitor cell transfer caused increased aortic sinus
atherosclerotic lesion size, as well as decreasing collagen
content, increasing ox-LDL and CD-3 positive lymphocytes,
indicative of a more vulnerable plaque [23]. Thus, novel
animal models are necessary to help elucidate which type
of stem cells is vital for the regression and stabilization
of coronary artery disease. In this regard, we report that
human coronary artery atherosclerotic disease contains cells
expressing ESC markers [15] and now an animal model in
rabbit is developed to help elucidate the role of these cells in
coronary artery disease.
The origin of smooth muscle cells within atherosclerotic
plaques is still unclear. Although initially it was suggested
that plaque remodelling was governed by local proliferating
plaque SMCs [24], further studies suggested these cells were
from the circulation [6]. However, these studies have now
been refuted, and current data have returned the emphasis
on local SMC [7, 8]. Although methodological differences
between these studies are of importance (harsh surgical
manipulation), we have used a gentle dietary manipulation
technique to address this question. In our study, we report
that spindle shaped smooth muscle cells that have formed
in the fibrous cap in the coronary artery do not express
any stem cell markers tested; however, other cells in the
plaque express both smooth muscle alpha actin and stem cell
markers. This data supports the hypothesis that fibrous cap
smooth muscle cells might not originate from the circulation
however, further experiments aimed at tracking blood borne
ESC+ cells will help understand the role of these cells in
atherogenesis.
The ability of cells in the blood vessel to acquire such
markers, upregulate such markers, or downregulate such
markers cannot be discounted. Cell fusion is a process
whereby cells can combine and share genetic material [25]
thus, it would be possible that cells entering from the lumen
could combine with cells present in the wall and express these
markers. In addition, evidence also exists whereby cells can
be stimulated to express embryonic markers [26], or might
be stimulated to switch the phenotype to a “synthetic” cell,
rather than “contractile” [27, 28]. Thus, further experiments
designed at identifying the origin of such cells are warranted.
Moreover, such cells could downregulate the expression of
these markers once the cells have homed into their specific
location, as it is clear that cells loose these makers during
differentiation [29, 30].
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Figure 2: Photomicrographs of serial adjacent sections of the left main coronary artery showing codistribution of SSEA-4, Tra-1-60, Oct-4,
SSEA-1, SSEA-3, and Tra1-81. SSEA4 positive cells were observed throughout the plaque ((a), scale bar 165 𝜇m) as also shown in Figure 1(d).
Clear endothelial-like cells were present overlying the fibrous cap ((b), exploded view, scale bar 33𝜇m, exploded view scale bar 15𝜇m);
however, not all cells that expressed SSEA-4 codistributed with Oct-4 ((c), scale bar 33 𝜇m, exploded view scale bar 15𝜇m), although the
copresence of endothelial SSEA1/SSEA3 was observed (Figures 2(d) and 2(e), scale bar 33 𝜇m, exploded view scale bar 15𝜇m). Interestingly,
there were no core cells that were positive for Tra1-60 (f) nor Tra1-81 (g) but were scarcely present either overlying the endothelial layer ((f),
Tra1-60 insert, scale bar 33 𝜇m, exploded view scale bar 15𝜇m) or just present beneath the endothelium ((g), scale bar 33𝜇m, exploded view
scale bar 15𝜇m). Negative control shows no positive signal ((h), scale bar 60𝜇m, exploded view scale bar 20𝜇m). As is also observed, no ESC
positive spindle shaped cells are present in the fibrous cap.
In these experiments using serial sections cut at five
microns, there is a possibility that the cells which are
identified as staining positive for each specific marker might
not be the identical cells in the serial section, even though the
staining pattern is very similar (dashed circles, Figures 1(a)
and 1(b)).Thus, the results presented here clearly indicate that
further experiments aimed at tracking specific populations
of stem cells and determining their final destination will
offer great insight into the origin of smooth muscle cells in
atherosclerotic plaques.
In summary, we show that cells expressing stem cell
markers are present within coronary artery plaques, which
could be very small embryonic-like cells and mesenchymal
stromal cells. In addition, it is shown that smooth muscle
cell 𝛼 actin positive cells within the fibrous cap of coronary
artery plaques do not express these stem cell markers,
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although macrophages (RAM-11+) and smooth muscle cells
𝛼 actin positive cells within the same plaques do express
these markers. This data indicates that the spindle shaped,
smooth muscle 𝛼 actin positive cells within fibrous cap
are a mature cell type and are most probably incapable
of further differentiation. In addition, it is suggested that
this animal model could be used to further study the role
of pharmacotherapy in the regulation of such cells, which
might be translatable to human coronary artery fibrous cap
formation and thus prevention of plaque rupture.
Conflict of Interests
The authors have no conflicts of interest.
Acknowledgments
This work was supported by the National Heart Foundation
of Australia and the National Health & Medical Research
Council of Australia. The authors would like to thank Pro-
fessor DavidHare, Department of Cardiology, Austin Health,
Heidelberg Australia, for providing infrastructure support.
References
[1] R. Corti, M. E. Farkouh, and J. J. Badimon, “The vulnerable
plaque and acute coronary syndromes,” American Journal of
Medicine, vol. 113, no. 8, pp. 668–680, 2002.
[2] T. Umemura and Y. Higashi, “Endothelial progenitor cells:
therapeutic target for cardiovascular diseases,” Journal of Phar-
macological Sciences, vol. 108, no. 1, pp. 1–6, 2008.
[3] P. E.Westerweel, F. L. J. Visseren, G. R. Hajer et al., “Endothelial
progenitor cell levels in obese men with the metabolic syn-
drome and the effect of simvastatin monotherapy vs. simvas-
tatin/ezetimibe combination therapy,” European Heart Journal,
vol. 29, no. 22, pp. 2808–2817, 2008.
[4] F. H. Bahlmann, K. de Groot, O. Mueller, B. Hertel, H. Haller,
and D. Fliser, “Stimulation of endothelial progenitor cells:
a new putative therapeutic effect of angiotensin II receptor
antagonists,” Hypertension, vol. 45, no. 4, pp. 526–529, 2005.
[5] C.-H. Wang, S. Verma, I.-C. Hsieh et al., “Enalapril increases
ischemia-induced endothelial progenitor cell mobilization
through manipulation of the CD26 system,” Journal of Molec-
ular and Cellular Cardiology, vol. 41, no. 1, pp. 34–43, 2006.
[6] M. Sata, A. Saiura, A. Kunisato et al., “Hematopoietic stem
cells differentiate into vascular cells that participate in the
pathogenesis of atherosclerosis,” Nature Medicine, vol. 8, no. 4,
pp. 403–409, 2002.
[7] J. F. Bentzon, C. S. Sondergaard, M. Kassem, and E. Falk,
“Smoothmuscle cells healing atherosclerotic plaque disruptions
are of local, not blood, origin in apolipoprotein E knockout
mice,” Circulation, vol. 116, no. 18, pp. 2053–2061, 2007.
[8] J. F. Bentzon, C. Weile, C. S. Sondergaard, J. Hindkjaer, M.
Kassem, and E. Falk, “Smooth muscle cells in atherosclerosis
originate from the local vessel wall and not circulating progen-
itor cells in apoE knockout mice,” Arteriosclerosis, Thrombosis,
and Vascular Biology, vol. 26, no. 12, pp. 2696–2702, 2006.
[9] W. Wojakowski, M. Kucia, R. Liu et al., “Circulating very small
embryonic-like stem cells in cardiovascular disease,” Journal of
Cardiovascular Translational Research, vol. 4, no. 2, pp. 138–144,
2011.
[10] W. Wojakowski, M. Kucia, E. Zuba-Surma et al., “Very small
embryonic-like stem cells in cardiovascular repair,” Pharmacol-
ogy andTherapeutics, vol. 129, no. 1, pp. 21–28, 2011.
[11] S. Berger and L. Lavie, “Endothelial progenitor cells in car-
diovascular disease and hypoxia—potential implications to
obstructive sleep apnea,” Translational Research, vol. 158, no. 1,
pp. 1–13, 2011.
[12] Y.-C. Huang, Z.-M. Yang, X.-H. Chen et al., “Isolation of
mesenchymal stem cells from human placental decidua basalis
and resistance to hypoxia and serum deprivation,” Stem Cell
Reviews and Reports, vol. 5, no. 3, pp. 247–255, 2009.
[13] A. Zulli, B. F. Buxton,M. J. Black, andD. L.Hare, “CD
34
Class III
positive cells are present in atherosclerotic plaques of the rabbit
model of atherosclerosis,” Histochemistry and Cell Biology, vol.
124, no. 6, pp. 517–522, 2005.
[14] A. Zulli, B. F. Buxton, M. J. Black, and D. L. Hare, “Embryonic
stem cells markers are present within rabbit atherosclerotic
plaques,” Histology and Histopathology, vol. 23, no. 6, pp. 741–
746, 2008.
[15] A. Zulli, B. F. Buxton, M. Merrilees, and D. L. Hare, “Human
diseased arteries contain cells expressing leukocytic and embry-
onic stem cell markers,” Human Pathology, vol. 39, no. 5, pp.
657–665, 2008.
[16] M. Pesce and H. R. Scho¨ler, “Oct-4: gatekeeper in the begin-
nings of mammalian development,” Stem Cells, vol. 19, no. 4, pp.
271–278, 2001.
[17] M. Yanagisawa and R. K. Yu, “The expression and functions of
glycoconjugates in neural stem cells,”Glycobiology, vol. 17, no. 7,
pp. 57R–74R, 2007.
[18] E. Gilboa, “The makings of a tumor rejection antigen,” Immu-
nity, vol. 11, no. 3, pp. 263–270, 1999.
[19] A. Zulli and D. L. Hare, “High dietary methionine plus
cholesterol stimulates early atherosclerosis and late fibrous cap
development which is associated with a decrease in GRP78
positive plaque cells,” International Journal of Experimental
Pathology, vol. 90, no. 3, pp. 311–320, 2009.
[20] A. Zulli, S. Rai, B. F. Buxton, L. M. Burrell, and D. L. Hare, “Co-
localization of angiotensin-converting enzyme 2-, octomer-
4- and CD34-positive cells in rabbit atherosclerotic plaques,”
Experimental Physiology, vol. 93, no. 5, pp. 564–569, 2008.
[21] C. Urbich and S. Dimmeler, “Endothelial progenitor cells: char-
acterization and role in vascular biology,” Circulation Research,
vol. 95, no. 4, pp. 343–353, 2004.
[22] J.-S. Silvestre, A. Gojova, V. Brun et al., “Transplantation of bone
marrow-derived mononuclear cells in ischemic apolipoprotein
E-knockout mice accelerates atherosclerosis without altering
plaque composition,” Circulation, vol. 108, no. 23, pp. 2839–
2842, 2003.
[23] J. George, A. Afek, A. Abashidze et al., “Transfer of endothelial
progenitor and bone marrow cells influences atherosclerotic
plaque size and composition in apolipoprotein E knockout
mice,”Arteriosclerosis,Thrombosis, andVascular Biology, vol. 25,
no. 12, pp. 2636–2641, 2005.
[24] P. Libby, “Inflammation in atherosclerosis,”Nature, vol. 420, no.
6917, pp. 868–874, 2002.
[25] S. Bonde, M. Pedram, R. Stultz, and N. Zavazava, “Cell fusion
of bone marrow cells and somatic cell reprogramming by
embryonic stem cells,” FASEB Journal, vol. 24, no. 2, pp. 364–
373, 2010.
6 Journal of Angiology
[26] M. Wang, J. Zhang, L.-Q. Jiang et al., “Proinflammatory profile
within the grossly normal aged human aortic wall,” Hyperten-
sion, vol. 50, no. 1, pp. 219–227, 2007.
[27] J. H. Campbell and G. R. Campbell, “The cell biology
of atherosclerosis—new developments,” Australian and New
Zealand Journal of Medicine, vol. 27, no. 4, pp. 497–500, 1997.
[28] R. J. Dilley, J. K. McGeachie, and F. J. Prendergast, “A review
of the proliferative behaviour, morphology and phenotypes of
vascular smooth muscle,” Atherosclerosis, vol. 63, no. 2-3, pp.
99–107, 1987.
[29] K. Noaksson, N. Zoric, X. Zeng et al., “Monitoring differentia-
tion of human embryonic stem cells using real-time PCR,” Stem
Cells, vol. 23, no. 10, pp. 1460–1467, 2005.
[30] J. R. Tejedo, R. Tapia-Limonchi, S. Mora-Castilla et al., “Low
concentrations of nitric oxide delay the differentiation of
embryonic stem cells and promote their survival,” Cell Death
and Disease, vol. 1, no. 10, article e80, 2010.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
